Lab News

Diane Ferris went to the March For Science in Washington

Diane Ferris and her son, Charlie Ferris Weiler were interviewed by the AAAS for their attendance at the March For Science in Washington.  She joined ...

READ MORE

Diane Ferris and her son, Charlie Ferris Weiler were interviewed by the AAAS for their attendance at the March For Science in Washington.  She joined the march in support of science while setting an example for her family.  

X Close

Amos Liang receives grant from BrightFocus Foundation to study Alzheimer’s disease

Our postdoctoral fellow Amos Jin Rui Liang will receive $100,000.00 grant from the BrightFocus Foundation for his study of Alzheimer’s disease...

READ MORE

Our postdoctoral fellow Amos Jin Rui Liang will receive $100,000.00 grant from the BrightFocus Foundation for his study of Alzheimer’s disease focusing on the “Identification of Novel ER-phagy Proteins that are Implicated in Neurodegeneration” 

X Close

#1 spot in the Media Highlights: The 10 Essential Stories of 2016

The top UC Berkeley story last year features our postdoctoral fellow Mark Dewitt using the CRISPR-Cas9 gene-editing tool to cure the sickle cell disease. ...

READ MORE

The top UC Berkeley story last year features our postdoctoral fellow Mark Dewitt using the CRISPR-Cas9 gene-editing tool to cure the sickle cell disease.  The #1 spot in the Media Highlights: The 10 Essential Stories of 2016.  His work was also picked up by dozens of sources, including the Los Angeles Times, Mercury News, Nature, The Scientist, Cosmos Magazine, and GenomeWeb. Roxanne Makasdjian and Stephen McNally produced a video that accompanied the press release and many versions of the story. 

X Close

Welcome, Jonathan Vu!

We're delighted to welcome Jonathan to join our lab as a Research Associate.  He has been working as a volunteer before and will continue to work with Mark DeWitt in the sickle cell research project.

Thomas Barnes from Intellia Therapeutics gave a talk to Corn Lab

The management and research teams from Intellia Therapeutics came to visit UC Berkeley today. Thomas Barnes, Ph.D., the Senior Vice President of Innovative...

READ MORE

The management and research teams from Intellia Therapeutics came to visit UC Berkeley today. Thomas Barnes, Ph.D., the Senior Vice President of Innovative Sciences & eXtellia, and his teams shared their scientific expertise in CRISPR/Cas9 technology and clinical development experience to the members in Corn lab.

X Close

Benjamin Gowen will attend the 2017 Immune Regulation in Autoimmunity and Cancer Keystone Conference

Corn Lab post-doc Benjamin Gowen is attending the 2017 Immune Regulation in Autoimmunity and Cancer Keystone Conference in Whistler, British Columbia ...

READ MORE

Corn Lab post-doc Benjamin Gowen is attending the 2017 Immune Regulation in Autoimmunity and Cancer Keystone Conference in Whistler, British Columbia from March 26-30, 2017.  If you’re attending the meeting, you should come by poster #1030 to see his work on the discovery of an autoimmunity-associated IL2RA enhancer. 

X Close

Benjamin Gomen gave a talk at 2017 Lorne Genome Conference

In February, Corn Lab post-doc Benjamin Gowen traveled to Australia to visit collaborators at the Commonwealth Scientific and Industrial Research Organisation...

READ MORE

In February, Corn Lab post-doc Benjamin Gowen traveled to Australia to visit collaborators at the Commonwealth Scientific and Industrial Research Organisation and  present his research at the 2017 Lorne Genome Conference. His talk was titled “Discovery of an autoimmunity-associated IL2RA enhancer by unbiased targeting of transcriptional activation” and featured work by members of the Corn Lab and Alex Marson’s lab at UCSF.

X Close

Big news in Corn Lab

Congratulations to Shaheen for becoming a new mother, Nicolas who just got married and Chris who was recently engaged!  All the best to you and your families at this special time!

 

CIRM grants $4M to fund sickle cell translation

The Corn lab and our collaborators have received a $4 million grant from the California Institute for Regenerative Medicine (CIRM) to develop CRISPR-Cas9...

READ MORE

The Corn lab and our collaborators have received a $4 million grant from the California Institute for Regenerative Medicine (CIRM) to develop CRISPR-Cas9 genome engineering into a cure for sickle cell disease (SCD).

This generous funding will support the fruitful ongoing collaboration between our lab, physicians and sickle cell experts Mark Walters and David Martin of UCSF Benioff Children’s Hospital Oakland Research Institute (CHORI), and stem cell and gene therapy specialist Don Kohn of UCLA.  The grant is part of CIRM’s Translational Award program, which aims to move “the most promising projects out of the laboratory and into clinical trials in people.” 

We are very grateful for CIRM’s support, which enables us to establish clinical protocols for gene surgery to cure sickle cell disease. CRISPR cures for genetic diseases are rapidly approaching the clinic, and our research will lay the groundwork for a clinical trial in SCD. Our clinical approach will involve removing stem cells from the bone marrow of sickle cell patients, editing the mutated DNA code with CRISPR-Cas9, and putting the corrected cells back into the patient, where they can persist and spawn healthy red blood cells. 

We recently published proof-of-concept sickle gene editing in Science Translational Medicine, and the funding from CIRM will enable us to improve the efficiency of editing, scale up the process, and perform more extensive studies in animals to ensure safety and accuracy before moving into human clinical trials. Mark DeWitt, a postdoc in the lab and first author on the Science Translational Medicine paper, will become the project’s Program Manager, managing research across the three campuses.

For a more in-depth perspective, read Jacob’s blog post on deploying gene editing to tackle sickle cell disease.

X Close

FILTERS

Tweets

Contact Us

Questions and/or comments about Corn Lab and its activities may be addressed to:

JACOB.CORN@BIOL.ETHZ.CH

Share: